Heavy Menstrual Bleeding Progestin Treatment in Bleeding Disorders Study
Public ClinicalTrials.gov record NCT05916469. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this multicenter prospective observational study and registry of U.S. adolescents and young adults with heritable bleeding disorders is to determine the bleeding outcomes, satisfaction, hemostatic parameter changes, and patient reported quality of life after 6 months of use of either of two commonly used hormonal treatments for menstrual suppression - levonorgestrel intrauterine device (LNG-IUD) and norethindrone acetate (NETA). Under this application the study will compare the two treatments and compare outcomes after LNG-IUD treatment results to a control group without a bleeding disorder, with the goal of determining the benefits and expected outcomes of these treatment options for this population.
Study identification
- NCT ID
- NCT05916469
- Recruitment status
- Recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 300 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 10 Years to 24 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 23, 2025
- Primary completion
- Nov 30, 2028
- Completion
- May 31, 2029
- Last update posted
- Dec 16, 2025
2025 – 2029
United States locations
- U.S. sites
- 9
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Stanford | Palo Alto | California | 94304 | Not yet recruiting |
| Colorado Anschutz Medical Campus | Aurora | Colorado | 80045 | Not yet recruiting |
| Emory | Atlanta | Georgia | 30322 | Not yet recruiting |
| University of Michigan Medicine | Ann Arbor | Michigan | 48109 | Not yet recruiting |
| Children's Mercy | Kansas City | Missouri | 64108 | Not yet recruiting |
| Oregon Health & Science University | Portland | Oregon | 97239 | Recruiting |
| Penn State Health | Hershey | Pennsylvania | 17003 | Not yet recruiting |
| University of Washington | Seattle | Washington | 98101 | Not yet recruiting |
| Seattle Children's Hospital | Seattle | Washington | 98105 | Not yet recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05916469, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 16, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05916469 live on ClinicalTrials.gov.